+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non-Invasive Prenatal Testing (NIPT) - Global Strategic Business Report

  • PDF Icon

    Report

  • 456 Pages
  • October 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 5303632
The global market for Non-Invasive Prenatal Testing (NIPT) was valued at US$3 Billion in 2025 and is projected to reach US$6.1 Billion by 2032, growing at a CAGR of 10.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Non-Invasive Prenatal Testing (NIPT) Market - Key Trends and Drivers Summarized

Why Is Non-Invasive Prenatal Testing (NIPT) Gaining Ground in Prenatal Care?

Non-Invasive Prenatal Testing (NIPT) is rapidly transforming prenatal care by offering expectant parents a safer and more accurate method for detecting chromosomal abnormalities in the fetus. NIPT analyzes cell-free fetal DNA present in the mother's blood to identify genetic conditions like Down syndrome, Edwards syndrome, and Patau syndrome. Unlike traditional invasive procedures like amniocentesis or chorionic villus sampling, which carry risks of miscarriage, NIPT provides reliable results with minimal risk. The test is typically performed during the first trimester and is suitable for high-risk pregnancies, enabling early decision-making and better management of prenatal care. As awareness of genetic screening increases, NIPT is becoming an integral part of routine prenatal screening.

What Are the Key Segments in the NIPT Market?

Key technologies include next-generation sequencing (NGS), microarray, and polymerase chain reaction (PCR), with NGS being the most widely used due to its high accuracy and ability to detect multiple genetic markers simultaneously. In terms of application, NIPT is primarily used for detecting trisomies, including Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). Other applications include detecting sex chromosome abnormalities and microdeletions. The major end-users of NIPT include hospitals, diagnostic laboratories, and maternity clinics, where genetic testing is becoming a standard component of prenatal care, particularly for women over 35 or those with a history of genetic disorders.

How Is NIPT Integrated Across Prenatal Care and Diagnostics?

Hospitals and maternity clinics are incorporating NIPT as part of routine prenatal screening for high-risk pregnancies, where early detection of chromosomal abnormalities is crucial for medical decision-making. Diagnostic laboratories use NIPT to offer comprehensive genetic screening services, often in collaboration with healthcare providers to ensure timely results and follow-up care. Research institutions are exploring the potential of NIPT beyond chromosomal abnormalities, including screening for single-gene disorders and broader genetic insights. Additionally, telehealth services are facilitating remote consultations and access to NIPT, making it more accessible to pregnant women in underserved regions. The growing awareness and acceptance of NIPT among healthcare providers and expectant parents underscore its role in modern prenatal care.

What Factors Are Driving the Growth in the Non-Invasive Prenatal Testing (NIPT) Market?

The growth in the Non-Invasive Prenatal Testing (NIPT) market is driven by several factors, including the increasing demand for early and accurate prenatal screening, particularly in high-risk pregnancies. Advances in next-generation sequencing and other genetic analysis technologies have improved the accuracy, efficiency, and affordability of NIPT, making it more accessible. The rising awareness of genetic disorders and the benefits of early detection have also contributed to the broader adoption of NIPT. Regulatory approvals for NIPT in several countries, combined with government support for maternal healthcare, have further fueled market growth. Additionally, the expansion of telehealth services and direct-to-consumer testing models has made NIPT more accessible, increasing its adoption among expectant mothers worldwide.

Report Scope

The report analyzes the Non-Invasive Prenatal Testing (NIPT) market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Product (Consumables & Reagents, Instruments); Method (Cell-free DNA in Maternal Plasma Tests, Ultrasound Detection, Biochemical Screening Tests); Application (Trisomy, Microdeletion Syndrome, Other Applications); End-Use (Diagnostic Laboratories, Hospitals).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Consumables & Reagents segment, which is expected to reach US$4 Billion by 2032 with a CAGR of a 8.8%. The Instruments segment is also set to grow at 14.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $822.8 Million in 2025, and China, forecasted to grow at an impressive 13.6% CAGR to reach $1.2 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Non-Invasive Prenatal Testing (NIPT) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-Invasive Prenatal Testing (NIPT) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Non-Invasive Prenatal Testing (NIPT) Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Agilent Technologies, Inc., Berry Genetics Inc., BGI Genomics Co. Ltd., Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche Ltd. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Non-Invasive Prenatal Testing (NIPT) market report include:

  • Agilent Technologies, Inc.
  • Berry Genetics Inc.
  • BGI Genomics Co. Ltd.
  • Eurofins LifeCodexx GmbH
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Igenomix
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Natera, Inc.
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • Yourgene Health

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agilent Technologies, Inc.
  • Berry Genetics Inc.
  • BGI Genomics Co. Ltd.
  • Eurofins LifeCodexx GmbH
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Igenomix
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Natera, Inc.
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • Yourgene Health

Table Information